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GASTROINTESTINAL ISSUES AND THE ROLE OF THE GUT MICROBIOTA 
IN CHILDREN WITH AUTISM SPECTRUM DISORDER 
 
MARIA NARVAEZ 
ABSTRACT 
 Autism spectrum disorder (ASD) is characterized by deficits in social 
communication and interaction as well as by repetitive patterns of behavior. It is thought 
to affect 1 in 68 children in the United States, yet researchers do not know what causes it 
and treatments are primarily focused on alleviating symptoms associated with ASD rather 
than treating any underlying cause. Various theories have been proposed over the years 
regarding what causes ASD in the hopes of finding effective treatment options. One of 
these theories, and the topic of this work, is that the intestinal bacteria play a role in the 
development of autism. The idea that gut bacteria may play a role in health and disease is 
one that has been gaining increased interest lately, and this has spread to the field of 
autism research.  
 Reports of children with ASD suffering from gastrointestinal (GI) issues are 
widespread, and even the first reports of children with ASD mentioned that some of them 
experienced GI symptoms or had issues with feeding. While GI symptoms are 
uncomfortable for any child, they pose special circumstances for those with ASD because 
these children are likely unable to effectively communicate what they are experiencing. 
This thesis will first review the prevalence of GI issues in children with ASD as well as 
discuss studies that have examined if there is a difference between the gut bacteria of 
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children with ASD compared to neurotypical children. As will be shown, many studies 
have in fact found a significant difference, but these differences vary across studies and a 
consensus has not been reached. Following this, the link between the gut bacteria and the 
brain, as well as how this relates to ASD will be discussed. Then, an overview of various 
treatment studies aimed at targeting the gut bacteria in animal models of ASD as well as 
in children with ASD will be analyzed.  
 While this field of research is certainly exciting, there is still a lot of work to be 
done by researchers. For one, the wide range of methodologies used and populations 
studied introduces variables that could be skewing the results and contributing to the lack 
of agreement between researchers regarding what bacterial strains might be relevant to 
ASD. Additionally, just because there is a correlation between certain bacterial strains 
and ASD does not mean it can be assumed that this is causing the development of ASD in 
so many children. Nonetheless, the fact that some treatment studies have led to 
improvements in ASD-related behaviors when targeting the gut bacteria of children 
indicates that this field of research is worthy of attention and continued support. 
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INTRODUCTION 
What is ASD? 
Autism was first described by Kanner in a paper published in 1943, in which he 
described children who lacked the “predisposition to be social” (Kanner, 1943). Since 
then, the defining characteristics of autism have undergone several revisions (Volkmar & 
McPartland, 2014). In the Diagnostic and Statistical Manual of Mental Disorders, 3rd 
edition (DSM–3) by the American Psychiatric Association (APA) (1980), ASD was 
divided into two groups, infantile autism and pervasive developmental disorder. Then, the 
APA’s Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-4) 
(1994) described five subtypes of autism which were autistic disorder, pervasive 
developmental disorder, Asperger disorder, childhood disintegrative disorder, and Rett’s 
disorder. The first three of these are now under the classification of autism spectrum 
disorder (ASD) in the APA’s Diagnostic and Statistical Manual of Mental Disorders, 5th 
edition (DSM–5) (2013), which defines ASD as a neurodevelopmental disorder 
characterized by “persistent deficits in social communication and social interaction across 
multiple contexts” as well as the presence of “restricted and repetitive patterns of 
behavior, interests, or activities.” Most children are diagnosed with ASD at around age 
two, and according to data from the Centers for Disease Control and Prevention (CDC), 
ASD affects 1 in 68 children aged 8 years old in the United States, with boys being four 
and a half times more commonly affected than girls (American Psychiatric Association, 
2013; Christensen, 2016). 
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Currently, there are two medications (risperidone and aripiprazole) that are widely 
used to treat some ASD-related behaviors, such as aggression and irritability (Choueiri & 
Zimmerman, 2017). While these medications may be helpful for some children, they are 
associated with many side effects such as weight gain, drowsiness, and fatigue (Masi, 
DeMayo, Glozier, & Guastella, 2017). Additionally, these drugs do not actually treat the 
core symptoms of ASD. To target ASD-related behavioral symptoms, the “gold-standard 
treatment” is behavioral intervention (Masi et al., 2017). Other types of therapies are also 
employed, such as occupational therapy, speech therapy, physical therapy, counseling, 
and social skills training (Choueiri & Zimmerman, 2017). 
The exact pathophysiology of ASD remains largely unknown, however there are 
various hypotheses that have been proposed. Per the DSM-5, there is evidence that about 
15% of cases of ASD are associated with a genetic mutation, but there are also various 
risk factors thought to be at play, including low birth weight, fetal exposure to valproate, 
or having older parents (American Psychiatric Association, 2013). Other researchers have 
also speculated whether maternal immune factors, metabolic dysregulation, or caesarean 
section might play a role in the progression of ASD (Buie, 2015). More recently, there 
has been an increasing amount of evidence for the role of the intestinal flora in the 
development of ASD. 
Before discussing the details of this interaction, the terms microbiota and 
microbiome should be defined because although these two terms are frequently used 
interchangeably, they are not the same. The microbiota is defined as the “microorganisms 
that live inside and on humans” whereas the microbiome is defined as the genomes of 
	3 
these organisms (Turnbaugh et al., 2007). Many researchers used the term microbiome 
when referring to the actual organisms, but for the sake of accuracy, the more specific 
definition of “gut microbiota” will be used when referring to the organisms that reside in 
the gut (Knight et al., 2017). 
While some review articles in recent years have discussed the role of the gut 
microbiota in ASD, the ultimate goal of this thesis is to provide a more detailed analysis 
of various studies in this field as well as to present some of the most relevant research 
over the years such that one can fully grasp how developments in this field have come 
about. Additionally, in the appendices, an overview of the various methods used across 
the field will be discussed so as to provide a framework for the analysis of the research 
done to date.  
ASD and Intestinal Permeability, Food Selectivity, and GI Symptoms 
While the core features of autism deal with behavior and communication, many 
children with ASD suffer from gastrointestinal symptoms, and even Kanner in 1943 
noted that five of the eleven children he studied had issues with food. He described how 
one of the children vomited a lot during the first year, another had to be tube fed all 
throughout her first year, and three others presented “severe feeding difficulty” (Kanner, 
1943). Likewise, in the DSM-5, it is noted that many children with ASD demonstrate 
extreme restrictions of food and that this “may be a presenting feature” of the disorder 
(American Psychiatric Association, 2013).  
One of the earliest studies found upon searching for GI related issues and ASD 
dates back to 1996, when researchers in Italy conducted a study to determine if the 
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intestinal permeability of children with autism (without GI symptoms) is different from 
control subjects. Using a sugar intestinal permeability test, where the recovery of 
mannitol and lactulose are measured in the urine, the authors found that nine out of 21 
children with autism had a high level of lactulose recovery, while none of the control 
subjects displayed abnormal recovery of either sugar (D’Eufemia et al., 1996). The 
authors state that there had been research prior to theirs in which it was found that autistic 
children had elevated levels of some peptides in their urine, so it was hypothesized that 
some peptides derived from food were able to pass through the intestinal barrier and 
contribute to behavioral abnormalities. It should be noted that some have called into 
question the reliability of using a sugar intestinal permeability test to determine the health 
of the intestinal mucosa (Vojdani, 2013). Nonetheless, this article by D’Eufemia et al. 
shows that interest in the intestinal permeability of children with ASD began over 20 
years ago.  
In regards to eating patterns in children with ASD, Bandini et al. (2010) looked at 
food selectivity in children with ASD compared to neurotypical children (those who are 
developing in a typical fashion). Food selectivity for the purposes of this study was 
categorized into either refusal of food, limited “food repertoire,” or “high-frequency 
single food intake (HFSFI)” (Bandini et al., 2010). The researchers found that children 
with ASD were found to display more food refusal as well as ate fewer types of food. 
While they were expecting to find a high incidence of HFSFI in children with ASD based 
on anecdotal reports they had heard, this was not the case. They note that this could be 
due to their definition of HFSFI being very specific. In both groups of children, limited 
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“food repertoire” was significantly associated with nutrient inadequacy (Bandini et al., 
2010). Since children with ASD were found to eat a smaller variety of foods, their 
findings about nutrient inadequacy imply that children with ASD are more likely to suffer 
from not receiving enough nutrients.  
Knowing that children with ASD are more likely to have issues with feeding, it is 
not all that surprising that reports of GI symptoms in this population occur. Various 
studies in recent years have tried to examine the exact prevalence of GI symptoms among 
children with autism, with reports ranging from 9 to 90% (Vuong & Hsiao, 2017). One 
study that retrospectively analyzed co-morbidities in over 14,000 children at four 
different hospitals in the Boston area found that 11.74% of children with ASD suffered 
from bowel disorders compared to only 4.5% of the overall hospital population (Kohane 
et al., 2012). The range in the percentage of children exhibiting GI symptoms is 
incredibly large, but it is clear that there are children with ASD who suffer from 
gastrointestinal issues. While GI issues are bothersome to any population, they can 
present different problems for children with ASD. For example, Buie et al. (2010) state 
that children with ASD who suffer from GI issues such as chronic abdominal pain or 
gastroesophageal reflux disease (GERD) and who have trouble communicating may 
manifest their discomfort via atypical behaviors such as displaying sleep disturbance, 
being aggressive, tapping on the area which bothers them, or restricting certain foods. 
Gorrindo et al. (2012) compared 40 children aged 5-18 with ASD+GI symptoms, 
45 children with only ASD, and 36 children with only GI symptoms. Of the children who 
had ASD+GI symptoms, the researchers found that constipation was the most commonly 
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diagnosed gastrointestinal issue with 85% of those children receiving the diagnosis from 
a pediatric gastroenterologist. In terms of factors associated with constipation, they found 
that children with ASD who were younger, more socially impaired, or nonverbal were 
more likely to experience this symptom. They also examined whether GI symptoms in 
children with ASD were associated with a limited diet, but there were no significant 
differences regarding the different types of foods/quantity of each food type eaten 
between the different groups. 
One particular study by Wang, Tancredi, and Thomas (2011) aimed at 
determining more definitively how prevalent GI symptoms in individuals with ASD 
really are. They note that population-based studies had reported rates between 9% and 
19%, and that clinical-based studies showed higher rates, however, they argue that the 
methods used in those studies were not reliable for various reasons such as lacking a 
control group or not using reliable assessments in the diagnosis of ASD patients (L. W. 
Wang et al., 2011). For their study, they examined 589 children that came from families 
in which there were at least two family members on the autism spectrum and compared 
them to their unaffected siblings. In order to confirm a diagnosis of ASD, they used the 
Autism Diagnostic Observation Schedule (ADOS) as well as the Autism Diagnostic 
Interview-Revised (ADI-R) (see Appendix I regarding techniques for ASD evaluation). It 
should be noted that Wang et al. (2011) grouped the ASD children into “full autism,” 
“almost autism,” or “spectrum subgroup” based on their results from ADOS and ADI-R. 
Any child that met the classification of autism based on both of these tests was classified 
as having “full autism.” Of all the children in those three categories, 42% had GI 
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problems and of those in the “full autism” group, 47% had GI problems. In comparison, 
only 12% of their unaffected siblings had any GI problems. The main issues reported for 
the children with ASD were constipation and chronic diarrhea, and the researchers found 
that children with more severe autism were more likely to have these GI problems. They 
note that theirs is the first study to determine if autism severity is associated with the 
prevalence of GI problems, although another article published in the same year also 
found that GI symptoms were strongly correlated with the severity of autism as measured 
by the Autism Treatment Evaluation Checklist (ATEC) (Adams, Johansen, Powell, Quig, 
& Rubin, 2011). 
Chaidez, Hansen, and Hertz-Picciotto (2014) completed a study which was the 
“largest ethnically diverse population based case-control study to date” comparing GI 
issues in almost 1,000 children in the United States with ASD, developmental delay, or 
typical development (TD). They also used ADOS and ADI-R to confirm a diagnosis of 
ASD, and like Wang et al., (2011) they grouped any child who met the autism 
classification of both tests into an autism group, while those that were close to reaching a 
classification of autism into an ASD group. They found that there was no statistical 
difference between these two groups in terms of ASD symptoms, so they grouped these 
individuals into one ASD group. Compared to children with TD, children with ASD were 
found to be over three times more likely to experience frequent GI problems, including 
abdominal pain, constipation, diarrhea, and vomiting. Using the Aberrant Behavior 
Checklist (ABC), Chaidez et al. (2014) also found that children with ASD and frequent 
episodes of abdominal pain, constipation, diarrhea, or gaseousness were more likely to 
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display irritability, social withdrawal, stereotypy, and hyperactivity. In their discussion, 
the authors discuss how it is “plausible” that children who deal with chronic GI issues 
and who have ASD may be more irritable and be more socially withdrawn due to their 
difficulty in communicating. 
A study by Tomova et al. (2015) also found that autism severity was positively 
and strongly correlated with the severity of GI dysfunction in children with ASD. The 
researchers used the Childhood Autism Rating Scale (CARS) (see Appendix I) and ADI 
to evaluate ASD symptoms, but it should be noted that this study was done in Slovakia 
and had a sample size of only 10 children with ASD. 
In contrast to studies that indicate that GI symptoms are positively correlated with 
increased ASD severity, a different study by Chandler et al. (2013) did not find this same 
association. Another more recent study conducted in Italy found that out of 163 
preschoolers, 25.8% experienced GI symptoms, with constipation and abdominal pain 
being the most common, however they acknowledge the fact that reports of prevalence of 
GI symptoms in other studies have varied greatly (Prosperi et al., 2017). They note that 
this variability could be due to the methods employed in collecting symptoms as well as 
the time frame being studied. In terms of the relationship between GI symptoms and ASD 
severity, Prosperi et al. (2017) found that children with ASD who suffered from GI 
symptoms tended to display higher autism severity as measured by ADOS Calibrated 
Severity Score (ADOS-CSS) (see Appendix I), but they do not declare this as being 
significant. They do however state that children with ASD suffering from GI issues 
displayed more stereotyped behavior as measured by a repetitive behavior scale.  
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Regardless of the exact percentage of children with ASD who experience food 
selectivity or GI symptoms, there is enough research to suggest that this is in fact a 
problem for some children with ASD, which makes it an important line of research. 
Due to the fact that some children with ASD show preference for specific foods, 
some may argue it is not surprising that various studies have found that the gut 
microbiota of children with ASD is different from that of typically developing children. It 
has been shown that eating specific diets over a long period of time may influence the 
groups of bacteria present in one’s gut (Wu et al., 2011). For example, Wu et al. found 
that increased presence of Bacteroides was associated with animal protein, some amino 
acids, and saturated fats, which the authors state is like a Western diet in which there is 
high meat consumption. Prevotella was associated with high consumption of 
carbohydrates and simple sugars, which they state is typical of agrarian societies. As 
Dinan and Cryan (2017) point out, the relationship between ASD and an altered gut 
microbiota is like the “chicken or egg issue.” In other words, is it that the food specificity 
shown by children with ASD is causing their altered gut microbiota, or is their gut 
microbiota contributing to their behaviors? 
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BACTERIA IMPLICATED IN ASD 
 
The earliest report implicating the role of a specific bacteria in ASD dates back to 
the late 1990s, when parents of children with regressive-onset autism found that their 
children exhibited changes in their behavior after being given antibiotics for otitis media 
which subsequently caused diarrhea (Bolte, 1998). The author hypothesized that children 
with this type of autism suffer from colonization of their intestinal tract by Clostridium 
tetani and that these bacteria produce a neurotoxin, called tetanus neurotoxin (TeNT), 
that directly causes neurological symptoms via traveling through the vagus nerve. A 
review of the literature regarding the mechasnism of action of TeNT provided no support 
for the idea that TeNT produced by C. tetani in the GI system might affect the CNS. 
Rather, the toxic effects of TeNT are produced when C. tetani colonize a wound and then 
the toxin enters the bloodstream and can bind to motor neurons at the neuromuscular 
junction (Surana et al., 2017). Even though Bolte’s hypothesis was incorrect, the reports 
which he based his hypothesis on urged other researchers, such as Finegold et al. (2002), 
to investigate whether there are specific gut bacteria associated with ASD. 
Finegold et al. (2002) provided the following reasons for why microorganisms 
should be considered as being involved in late-onset autism: “(1) onset of the disease 
often follows antimicrobial therapy, (2) gastrointestinal symptoms are common at onset 
and often persist, (3) other antimicrobials (e.g., oral vancomycin) may lead to a clear-cut 
response . . ., (4) some patients have responded to several courses of vancomycin and 
relapsed each time it was discontinued.” In line with their hypothesis, they found, based 
on stool samples, that children with ASD had increased levels of Clostridium and 
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Ruminococcus spp. compared to control children and that there were specific species 
from these groups unique to children with ASD. 
A study by Song, Liu, and Finegold (2004) used real-time polymerase chain 
reaction (PCR) to quantitate the levels of three clusters of Clostridium as well as one 
specific Clostridium species in the stool of children with ASD. The authors note that the 
method used previously by Finegold et al. (2002) relied on sequence data from cultures 
of bacteria, and they state that these methods are not as reliable as culture-independent 
techniques. Based on their new methods, they found that mean counts of Clostridium 
boltae as well as of Clostridium clusters I and XI were significantly greater in children 
with late-onset autism compared to control children. Counts for cluster XIVab however 
were not significantly different.  
Since these early studies, many studies have aimed to identify possible differences 
in the intestinal flora of children with ASD compared to neurotypical children. Giving an 
in depth overview of all of these articles is beyond the scope of this thesis due to the 
number of published studies related to the topic. However, Ding, Taur, and Walkup 
(2017) compiled some of this data into a phylogenetic tree, which is a useful way of 
visualizing some of the differences in the bacterial species present in children with ASD 
(Figure 1). Additionally, a recent review article by Vuong and Hsiao (2017) summarized 
some of these studies into a table, which has been modified with additional information 
and additional studies (Table 1).
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Figure 1: Alterations of the gut microbiota in ASD as determined by various 
studies. “Results of studies are shown on a phylogenetic tree. Tree tips (circles) 
represent bacterial species known to colonize humans; color denotes phylum-level 
classification. Bacterial taxa (blue shaded areas) studied are shown, at various levels of 
classification. Study findings (squares) are listed for each bacterial taxon; color denotes 
direction of change observed in ASD. Studies vary considerably by design, sample size, 
molecular approach, and analysis. *Sutterellaceae is a new family originally from 
Alicaligenaceae. **Correlation was with unclassified Veillonellaceae.” Figure and Legend 
taken from Ding et al. (2017).
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Table 1. Findings from various studies over the years regarding bacterial species 
altered in ASD. Adapted from Vuong and Hsiao (2017) with additional notes added 
Description Sample Size Source/Location 
More clostridial species in ASD group. Those in 
the ASD group all had GI symptoms (diarrhea or 
constipation). 
13 ASD children; 
8 controls 
(Finegold et al., 
2002) Chicago 
ASD group had more Clostridium boltae and 
more Clostridium group I and XI. 
15 ASD children; 
8 controls 
(Song et al., 2004) 
Chicago 
ASD patients had more bacteria from Clostridium 
clusters I and II. Used FISH technique. 
58 ASD patients; 
22 controls 
(Parracho et al., 
2010) England 
Pyrosequencing results showed more 
Bacteroidetes in ASD children as well as more 
Desulfovibrio species and Bacteroides vulgatus. 
The ASD children in this study all had GI 
symptoms. More Firmicutes in the control group. 
33 ASD patients (Finegold et al., 
2010) Oregon and 
California 
ASD patients with GI symptoms had less 
Bacteroidetes and an increase in 
Firmicutes/Bacteroidetes ratio. 
15 ASD patients; 
7 control patients 
(Williams et al., 
2011) New York 
Children with ASD had less Bifidobacterium and 
Enterococcus. They also had much higher levels 
of Lactobacillus. Used Vitek 2 identification cards 
for gram positive and gram negative organisms 
as well as yeast. 
58 ASD patients 
with GI 
symptoms; 39 
controls 
(Adams et al., 
2011) Arizona 
No difference in bacterial species or in bacterial 
diversity between groups. Note: about half of the 
ASD group had GI symptoms while the others did 
not.  
51 ASD patients; 
53 controls 
(siblings) 
(Gondalia et al., 
2012) Australia 
Less Bifidobacterium, more Bacteroidetes, and 
more Clostridium in ASD. Of bacteria in fecal 
samples of ASD patients, Caloramator, Sarcina, 
and Clostridium were present in the highest 
amounts. 
10 ASD patients; 
10 controls 
(siblings) 
(De Angelis et al., 
2013) Italy 
Increased Sutterella species and Ruminococcus 
torques in children with ASD. 
23 ASD patients; 
31 controls (22 
were siblings) 
(L. Wang et al., 
2013) Australia 
Decreased Bacteroidetes/Firmicutes ratio. Levels 
of Desulfovibrio were not significantly different 
between groups, but higher levels of this species 
were associated with autism severity. 
10 ASD patients; 
10 controls 
(Tomova et al., 
2015) Slovakia 
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GUT MICROBIOTA COMMUNICATION AND DEVELOPMENT 
The Link Between the Gut and the Brain 
The ways in which the CNS can modulate motility, secretion, and blood flow of 
the gut via the autonomic nervous system (ANS) is a topic that has been well researched 
and is taught widely. Likewise, communication in the opposite direction, from the gut to 
the brain, has also been studied in depth. In a review by Rhee et al. it is discussed how the 
vagus nerve can transmit information from the gut to the CNS and that there are nerve 
terminals of vagal afferents that are found close to enterochromaffin cells (EC) (Rhee, 
Pothoulakis, & Mayer, 2009). These cells release serotonin as well as other signaling 
peptides, so it was proposed that this connection between EC cells and the vagus nerve 
could be a path for communication between chemical stimuli in the lumen of the gut and 
the CNS. The role of the gut microbiota in this line of communication is a topic that has 
been gaining more momentum in recent years since the 2000s and there have been studies  
which have indicated that the vagus nerve is in fact important for this bidirectional 
communication between the gut microbiota and the CNS (Dinan & Cryan, 2017). 
In one study, it was found that Lactobacillus rhamnosus was able to regulate 
emotional behavior in mice as well as gamma-aminobutyric acid (GABA) receptor 
expression via the vagus nerve (Bravo et al., 2011). The researchers determined that the 
vagus nerve was crucial for this relationship because mice that had undergone vagotomy 
did not experience the same effects. GABA is the main inhibitory neurotransmitter in the 
central nervous system (CNS) and it is thought to play a role in anxiety and depression 
(Bravo et al., 2011). Therefore, the fact that a particular strain of bacteria could modulate 
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the expression of the GABA receptor is very interesting. Additionally, the fact that the 
vagus nerve was necessary for this effect adds evidence for its role in the gut-brain axis. 
While this route of communication seems likely in a healthy state, it is possible that a 
diseased state causing increased intestinal permeability could allow bacterial products 
and inflammatory molecules to access nerve terminals (Clapp et al., 2017; Rhee et al., 
2009). 
Microbes in the gut have been found to be able to regulate important central 
neurotransmitters like serotonin and there have even been studies indicating that some 
bacteria can synthesize and release neurotransmitters (Dinan & Cryan, 2017). For 
example, Lactobacillus and Bifidobacterium can make GABA, and additionally, they can 
increase intestinal motility (Dinan & Cryan, 2017; Rhee et al., 2009). Some Escherichia, 
Bacillus, and Saccharomyces species are able to make noradrenaline, and some 
Escherichia species can also make serotonin (Dinan & Cryan, 2017). Per Dinan and 
Cryan, these neurotransmitters likely act directly on the enteric nervous system rather 
than on the CNS, because they are unable to cross the blood-brain barrier (BBB). These 
researchers also suggest two other ways in which the gut microbiota may influence the 
brain. The first is via the release of products of their metabolism, such as short chain fatty 
acids (SCFAs) like butyrate, propionate, and acetate. And the second is through 
cytokines, which can travel to the brain and may be able to communicate across the BBB. 
They note that two cytokines in particular, IL-1 and IL-6, are able to activate the 
hypothalamic-pituitary-adrenal (HPA) axis. This then leads to cortisol release, which 
activates the stress system (Figure 2) (Dinan & Cryan, 2017). SCFAs are produced as a 
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result of the fermentation of dietary fiber by anaerobic organisms and therefore, the levels 
are thought to be representative of the concentration of bacteria in the gut as well as the 
amount of soluble fiber being consumed (Adams et al., 2011). 
 
Figure 2: Communication between gut microbes and the brain. “These include the 
vagus nerve, SCFAs (butyrate, propionate, and acetate), cytokines, and tryptophan. 
ACTH, adrenocorticotropic hormone; CRH, corticotropin releasing hormone.” Figure and 
legend taken from Dinan and Cryan (2017). 
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The microbiota plays a role in health and is able to influence the development of 
many organ systems including the immune system (Rook, Bäckhed, Levin, McFall-Ngai, 
& McLean, 2017). A healthy state has been associated with high gut bacterial diversity 
due to “resilience afforded by higher functional redundancy” (Kang et al., 2017). 
Sommer, Anderson, Bharti, Raes, and Rosenstiel (2017) note that this stability is 
important for maintaining the integrity of the intestinal mucosal barrier and that when the 
state of equilibrium is disrupted, dysbiosis occurs and disease can follow. Changes in the 
gut microbiota have been found to be associated with several diseases that affect children 
including allergies, inflammatory bowel disease (IBD), and type I diabetes mellitus 
(Slattery, MacFabe, & Frye, 2016). While Slattery et al. seem optimistic that targeting the 
gut microbiota as a way to treat certain conditions has promise, they do caution that there 
is not enough information about the long term effects of this type of treatment. They 
worry that treating the initial condition through changing the gut microbiota may then 
predispose children to other conditions. As an example, they note that while antimicrobial 
treatment for Heliobacter pylori reduces the likelihood of a patient developing peptic and 
duodenal ulcers, it can also increase the risk of esophageal cancer. Additionally, they 
argue that because children are unable to give consent, it would not be appropriate to 
initiate these types of treatments without first knowing what the long term effects are.  
While many of the exact mechanisms by which bacteria modulate health and 
disease are not fully known, this relationship has been studied by many in recent years 
and in regards to autism, researchers have tried targeting the gut microbiota in hopes of 
improving both ASD-related symptoms and GI symptoms. Before discussing these 
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studies, the way in which the gut microbiota develops in humans will be discussed 
briefly. 
Development of the Gut Microbiota 
Previously, it was thought that the gut of neonates was colonized at the time of 
birth, when an infant passes through the birth canal, however, more recent research 
suggests it begins even earlier (Slattery et al., 2016; Walker, Clemente, Peter, & Loos, 
2017). Studies have found that the placenta and meconium both have distinct 
microbiomes, so it is now believed that the development of the gut microbiome begins in 
utero (Slattery et al., 2016). Its continued development is thought to be affected by 
delivery mode, diet, breastfeeding, how old the child’s mother is at the time of birth, 
body mass index (BMI), antibiotic use, and maternal stress (Munyaka, Khafipour, & 
Ghia, 2014; Walker et al., 2017). Maximum diversity is thought to be reached during 
adolescence, and then it declines in older adults (Ho & Ross, 2017). 
 One study examining the development of the gut microbiota in children during the 
first year of life found that vaginally delivered children had a more similar gut microbiota 
to their mothers compared to children delivered by C-section (Bäckhed et al., 2015). 
These researchers also determined that nutrition played a role in the development of the 
gut microbiota, with children who were breast-fed up until one year having different 
bacteria present in their gut compared to those who had stopped breast-feeding. Diet can 
also have a profound impact on the organisms present in an individual’s gut microbiota, 
so it is important to take this into account when trying to compare different populations 
(Wu et al., 2011). Another factor that can affect the gut microbiota is antibiotic use. 
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Broad-spectrum antibiotics reduce the diversity of fecal microbiota and their use has been 
tied to the presence of GI symptoms (Cryan & O’Mahony, 2011). 
 Over time, the gut microbiota changes greatly, and the species it contains play an 
important role in human processes including nutrient metabolism, synthesis of vitamin K, 
metabolism of xenobiotics and drugs, and protection from pathogenic organisms 
(Jandhyala et al., 2015; Rook et al., 2017). The vast majority of bacteria in the gut of 
healthy adults belong to one of two phyla, Firmicutes or Bacteroidetes (Figure 3) (Knight 
et al., 2017; Rook et al., 2017; Turnbaugh et al., 2007). 
 
 
 
 
 
 
Figure 3: Development of the human gut microbiota. “In the adult, this development 
is dominated by two phyla: Bacteroidetes (Bacteroides) and Firmicutes (Clostridium, 
Faecalibacterium, Eubacterium), which replace the early dominance of Actinobacteria 
(Bifidobacterium) and Proteobacteria (Escherichia). The windows of opportunity for the 
correct establishment of the immune system, metabolic system, gut–brain axis, and 
stress responses could occur during the periods of complex change between birth and 
adulthood. These crucial windows are documented in animal models, but not yet in 
human beings.” Figure and legend taken from Rook et al. (2017). 
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Compared to the number of human genes we have (about 20,000), our bodies are 
associated with 2-20 million microbial genes, which is at least 100 times more than the 
number of our own genes (Knight et al., 2017). In terms of cells, the most commonly 
cited estimate for the number of microbial cells in humans is 1014, which was thought to 
be 10 times the amount of human cells present (Sender, Fuchs, & Milo, 2016). However, 
after revisiting those calculations, Sender et al. found that the ratio is much closer to 1:1. 
Regardless of which is correct, microbes constitute a significant part of our bodies, so it 
is not surprising that these microbes can play a role in disease processes. 
In regards to autism, one study, which will be discussed in further detail later, 
noted that in the individuals they studied, compared to neurotypical children, more 
children with ASD were delivered by C-section (61% vs. 15%) and more were fed non-
standard formula as infants (39% vs. 5%) (Kang et al., 2017). The children with ASD had 
been breast-fed for an average of 3.0 months while the neurotypical children had been 
breast-fed for an average of 8.8 months (Kang et al., 2017). Additionally, the mothers of 
children with ASD had consumed significantly less fiber than those of neurotypical 
children, something that could have been true during their pregnancy and could have 
affected the gut microbiota of their children. Given that mode of birth and diet have been 
found to affect the gut microbiota, it is interesting that there was a difference in these two 
regards when comparing an ASD group to a neurotypical group. 
A Note About the Role of Yeast and Phage Populations in the Gut 
Research on the gut microbiota has been largely focused on bacterial populations. 
For this reason, the focus of this work is on the role of bacteria in ASD. However, it is 
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important to note that this collection of organisms also encompasses fungi, protozoa, and 
viruses including phages (Rook et al., 2017). 
Some studies have implicated yeast in the development of ASD. For example, 
Burrus (2012) hypothesized that Candida albicans could play a role in ASD for a subset 
of patients. He said that this particular yeast species produces ammonia, and that when 
this combines with propionic acid, beta-alanine may be synthesized, which is structurally 
similar to GABA, the main inhibitory neurotransmitter. He notes that other studies found 
that beta-alanine is higher in children with ASD and that prior studies had shown it can 
cross the BBB. However, a search for articles regarding whether beta-alanine does in fact 
cross the BBB and if it is able to mimic the actions of GABA did not provide any results, 
but maybe future studies will examine this possible link. Plasma levels of GABA have 
been found to be elevated in children with ASD compared to controls, but GABA is 
unable to cross the BBB, so it is not clear what role increased plasma levels of GABA or 
beta-alanine in children with ASD would have (Al-Otaish et al., 2018; Coghlan et al., 
2012). Studies examining GABA levels in the brains of children with ASD have actually 
found low GABA levels. For example, Puts et al. (2017), found that children with ASD 
have low levels of GABA in the sensorimotor cortex and that this is associated with 
impairments in the processing of tactile information seen in this group. Some researchers 
believe that low levels of GABA in some areas of the brain, such as in the motor cortex, 
the visual cortex, and the auditory cortex, may be responsible for a hyperexcitable state in 
children with ASD (Takarae & Sweeney, 2017). 
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In terms of the yeast species present, Kantarcioglu et al. (2016) found that 
Candida albicans was the most common species isolated from the stool samples of 
children with ASD. This is important because while this species is normally present in 
the GI system, unusually high levels can decrease absorption of carbohydrates and 
minerals (Kantarcioglu et al., 2016). Another study which aimed to examine the phage 
population in an ASD group did not see any changes after a particular treatment plan 
(Kang et al., 2017). However, they point out that changes in phage diversity can occur 
more slowly than for bacteria, so it is possible they their study did not span enough time 
to see these changes.  
Now that it has been shown that GI problems in children with ASD is a recurring 
theme in the literature and that many studies have found a difference in the gut 
microbiota of children with ASD, the remainder of this thesis will focus on treatment 
studies that have been done in recent years. First, a few studies done in animal models 
will be reviewed, and then those done in humans will be analyzed. 
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TREATMENT STUDIES TARGETING THE GUT MICROBIOTA IN MICE 
One mouse study, by Hsiao et al., (2013) used a maternal immune activation 
(MIA) model, which displays features common to ASD including “communicative, 
social, and stereotyped impairments,” to study the GI barrier and gut microbiota in mice. 
Compared to controls, adult MIA offspring were found to have a significant decrease in 
the integrity of their intestinal barrier as measured by increased movement of fluorescein 
isothiocyanate–dextran (FITC-dextran) from the gut into the circulation as well as 
decreased gene expression in the colon of tight junction proteins, occludin, and claudin 8, 
which are responsible for regulating membrane permeability. Gene expression of claudin 
15 was actually increased in this population, but the authors do not propose an 
explanation for this. They also found that compared to control mice, colons of MIA 
offspring had higher levels of interleukin-6 (IL-6) mRNA and protein. They state that this 
is in line with the idea that gut permeability is associated with alterations in the immune 
response. In terms of gut microbiota, the authors found that based on unweighted UniFrac 
analysis (see Appendix II), there was a significant difference between the species present 
in MIA offspring compared to controls. Specifically, they found that this difference was 
primarily driven by changes in the Clostridia and Bacteroida classes. 
 Hsiao et al. (2013) then treated MIA offspring with Bacteroides fragilis at 
weaning and found that this treatment was able to correct the increased intestinal 
permeability in MIA offspring, reduce their colon IL-6 mRNA and protein levels, and 
also increase the relative abundance of six bacterial species that were significantly 
decreased in this group prior to treatment. This treatment also improved certain ASD-
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related behaviors including anxiety-like behavior, issues with communicating, and 
repetitive behavior. The authors note that there was no evidence to indicate that B. 
fragilis had colonized the gut of these mice, so they suggest that the effects seen could be 
due to the treatment causing “persistent shifts in the compositions of resident 
microbiota.” Interestingly, they saw an improvement in these behaviors after treatment 
with a different species of the Bacteroida class, Bacteroides thetaiotaomicron.  
Hsiao et al. (2013) argue that the way in which probiotic treatment is able to 
correct gut permeability and improve behavioral symptoms is through its effect on 
metabolites. Prior to treatment, MIA offspring displayed about an 8% difference, that was 
statistically significant, in serum metabolites present compared to control offspring. MIA 
offspring showed levels of 4-ethylphenylsulfate (4EPS) that were 46-fold higher than in 
controls as well as significantly higher levels of serum indolepyruvate and serotonin. 
Interestingly, adding 4EPS to wild type mice caused anxiety-like behavior, similar to 
what they saw in MIA offspring. Indolepyruvate is a product of tryptophan catabolism 
and is thought to be produced by gut microbes. Treatment with B. fragilis was able to 
correct the levels of both 4EPS and indolepyruvate to resemble levels found in control 
offspring. It should be noted that 4EPS and indolepyruvate have not been confirmed as 
being implicated in ASD. However, given the fact that treatment with B. fragilis 
ultimately led to improvements in ASD-related behavioral symtpoms, it is interesting that 
this improvement was accompanied by a change in the levels of these two metabolites.  
Another mouse study, by Buffington et al. (2016), looked at the effects of 
maternal high-fat diet (MHFD) on behavior and the gut microbiota of mice. Offspring 
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born to mothers receiving MHFD were found to have social deficits in line with the 
deficient social interactions seen in ASD, such as impaired sociability and lack of interest 
in social novelty. In addition, and in support of the authors’ hypothesis that lack of 
certain bacterial species can cause social deficits, they found that germ-free mice showed 
impaired social behavior. These mice reverted to having normal behavior if they received 
fecal microbiota from offspring of mothers eating a regular diet at 4 weeks, but not at 8 
weeks. In comparing the feces of offspring born to MHFD mothers with those born to 
mothers having a regular diet, the authors found that there was a significant difference 
between the bacterial community structures when using unweighted UniFrac analysis but 
not when using weighted UniFrac analysis (see Appendix II for differences between these 
methods).  
Buffington et al. (2016) used metagenomic shotgun sequencing to determine if 
there were any particular species that were missing in the fecal samples from MHFD 
offspring and found that L. reuteri was decreased more than 9-fold compared to offspring 
born to mothers fed a regular diet. The authors note that L. reuteri has been found to 
promote oxytocin levels, which plays a role in social behaviors, so they hypothesized that 
the decrease in L. reuteri seen in MHFD offspring could be causing their social deficits. 
To test this, they supplemented the water of MHFD offspring with L. reuteri and found 
that this led to a significant improvement in sociability and preference for social novelty. 
However, they do note that some of the behavioral changes seen in MHFD offspring, 
such as anxiety and engaging in repetitive behavior, were unchanged with L. reuteri 
treatment. Since this bacteria is known to promote oxytocin levels, the authors examined 
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whether MHFD offspring showed any difference in the number of oxytocin-expressing 
cells in the paraventricular nucleus (PVN) of the hypothalamus, which is the main site of 
synthesis for oxytocin. They found that MHFD offspring did in fact have less oxytocin 
immunoreactive neurons, and that this decrease was restored with L. reuteri treatment. In 
regards to how L. reuteri might be able to increase oxytocin levels in the brain, 
Buffington et al. (2016) say they “favor the idea that the vagus nerve could be the main 
pathway of communication between the gut/L. Reuteri and changes in oxytocin in the 
PVN.” The ability of L. reuteri to increase levels of oxytocin via the vagus nerve has in 
fact been proven. In a mouse model for wound healing, Poutahidis et al. (2013) found 
that mice who received L. reuteri treatment showed increased levels of oxytocin and that 
this effect was abolished following vagotomy. Interestingly, treatment with nasal 
oxytocin has previously been studied in children with ASD. For example, one study 
found that 5 weeks of twice daily administration of a nasal spray containing oxytocin led 
to improvements in the social responsiveness of children with ASD (Yatawara, Einfeld, 
Hickie, Davenport, & Guastella, 2016). 
 While the aforementioned mice studies show promising results, it is important to 
keep in mind that these findings are not directly relatable to humans because, as Cryan 
and O’Mahoney (2011) point out, mouse studies “do not represent any true situation in 
the human population.”
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TREATMENT STUDIES TARGETING THE GUT MICROBIOTA IN HUMANS 
Several studies in recent years have attempted to target the gut microbiota of 
children with ASD in the hopes of improving some of their ASD symptoms. These 
studies have used various techniques including modified diets, prebiotics, probiotics, 
antibiotics, and microbiota transfer. Below, some of the most promising studies will be 
summarized and analyzed by type of treatment to get a sense of how the field has evolved 
in recent years.  
Diet Modifications 
 Targeting the gut microbiota of children with ASD by changing their diet is 
arguably one of the less invasive methods that researchers have employed over the years. 
The main elimination diet that has been used in children with ASD is a gluten-free and 
casein-free (GFCF) diet (Ly et al., 2017). Many studies have looked at the effects of this 
diet on ASD, so many that a review of all of them would not be possible here. The reason 
this type of diet has been of interest to researchers is because there was a theory, first 
proposed by Panksepp (1979), that “opioid excess” might be linked to ASD. He proposed 
that the opiate system of children with ASD was overactive. Later, researchers postulated 
that the metabolism of gluten and casein peptides creates opioid peptides that can cross 
the intestinal barrier due to the high gut permeability seen in ASD and then bind to opioid 
receptors and lead to behavioral abnormalities (D’Eufemia et al., 1996). However, many 
studies have failed to find abnormally high levels of opioid peptides in children with 
ASD, so this theory is not well supported (Cass et al., 2008; Ly et al., 2017). Nontheless, 
the idea that a GFCF diet may improve ASD-related symtpoms persists.  
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One systematic review of studies examining the effect of a GFCF diet analyzed 
the six randomized controlled trials that had been published between 2007 and August of 
2016 (Piwowarczyk, Horvath, Łukasik, Pisula, & Szajewska, 2017). The studies that 
Piwowarczyz et al. (2017) analyzed had a total of 214 participants, with half in a GFCF 
group and half in a control group, and the children in all but one study had their diagnosis 
of ASD confirmed by ADI-R and/or ADOS. After their thorough analyses of the six 
studies available, the researchers determined that there is a lack of consistent evidence in 
support of using a GFCF diet in children with ASD. They showed that some studies did 
show statistically significant improvements in certain scores, however these were not 
measured by standardized scales and some were subject to parental bias since the parents 
of the children were rating their child’s symptoms. Ly et al. (2017) noted in a recent 
review article regarding elimination diets in ASD that there is not enough evidence to 
conclude that a GFCF diet is beneficial for treating ASD symptoms. 
Prebiotics 
 One study by Grimaldi et al. (2017) examined the effects of a prebiotic on the 
fecal bacteria present as well as the metabolic activity in children with ASD. Prebiotics 
are “food ingredients that contain non-digestible oligosaccharides” (Jandhyala et al., 
2015). Grimaldi et al. (2017) administered galactooligosaccharide (B-GOS) to three 
children with mild autism and three control children, none of whom had any GI 
complaints. The methods they used were somewhat unique to other studies presented 
here in that they made a “gut model system” composed of three compartments to model 
the proximal, transverse, and distal colon. Prior to treatment, the children with ASD had 
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lower levels of Bifidobacterium compared to the control children and after treatment, 
these levels increased. They also reported a significant increase in Clostridium cluster XI 
following B-GOS treatment. Samples from children with ASD had lower levels of 
butyrate and propionate compared to those from the controls, and they found that B-GOS 
increased the amount of acetate and butyrate detected in the compartment modeling the 
proximal and transverse colon. Also after B-GOS treatment, propionate was decreased in 
samples from children with ASD in the compartment representing the distal colon. If the 
theory that propionate can lead to harmful effects in the brain is correct, this study shows 
that B-GOS could help with this. Obvious limitations with this study include its small 
sample size. Additionally, some of the conclusions they make do not seem to be directly 
supported by their graphical data. However, this study was included here to give an 
example of a study targeting the gut microbiota through a prebiotic. 
Probiotics 
There are several studies that have looked at the effects of probiotics on groups of 
children with ASD as well as one case study. Probiotics are commonly used in the 
treatment of GI disorders, and in recent years have been used in children with ASD to see 
if they might be able to regulate dysbiosis of the gut microbiota and thereby improve 
ASD symptoms. By definition, probiotics are live microorganisms that are thought to 
stabilize the mucosal barrier in the gut (Santocchi et al., 2016). They have been found to 
have a balancing role on the bacteria in the gut and are able to decrease proliferation of 
Clostridium species (Santocchi et al., 2016). The group studies done to date on probiotics 
as well as a case study will now be summarized and analyzed. 
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 The first study found, which was conducted by Parracho et al., (2010) was a 
placebo-controlled blinded study in which 17 children with ASD from the UK were 
treated with a probiotic (Lactobacillus plantarum WCSF1) for 12 weeks. Based on fecal 
sampling, they found that children who received probiotic had significantly higher counts 
of bacteria in the lactobacilli/enterococci group and lower counts of bacteria in 
Clostridium Cluster XIVa compared to those who received placebo. While many other 
studies have relied on sequencing methods to determine the prevalence of different 
bacterial strains, the authors of this study chose to use fluorescence in situ hybridization 
(FISH). This entailed using six specific probes known to allow the visualization of 
particular bacterial groups. The authors do mention that less than 50% of the total 
bacterial count was covered by the probes used, so it is possible that there may have been 
differences between the two groups in regards to other bacterial groups. There was no 
difference between the two groups in terms of GI symptoms, but it should be noted that 
the children recruited for this study did not have GI symptoms, so it would not be 
expected for GI symptoms to be improved. In terms of behavior, children who received 
the probiotic had improved scores on some of the sub-scales in the Total Behaviour 
Problem Score (TBPS) (see Appendix I). While this study showed some significant 
results, the authors state that they had originally recruited 62 children but that many 
dropped out due to the study design. They note that collecting six fecal samples as well as 
keeping a daily diary “may have been over-ambitious for this subject group” (Parracho et 
al., 2010). No other studies reviewed have pointed this out as clearly as this group did, 
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but it is something that researchers must keep in mind when working with patients who 
have ASD.  
The next study that mentioned the effects of probiotics on ASD was not a 
treatment study, but rather the researchers asked whether or not each child was already 
taking a probiotic at the beginning of the study and they included this as a variable in 
their analysis (Adams et al., 2011). They studied 58 children with ASD and 39 control 
children, and found that 33% of the children with ASD were taking probiotics while only 
5% of the control children were taking probiotics. When comparing the entire ASD group 
to the non-ASD control group, they found that children with ASD had lower levels of 
SCFAs in their stool. In interpreting these results, the authors suggest that the decreased 
SCFA levels in children with ASD compared to the controls could be due to lower 
amounts of good bacteria that make SCFAs, decreased soluble fiber intake, longer transit 
time, and/or increased intestinal permeability. Since the authors did not measure SCFA 
levels in the bloodstream, they were not able to determine which of these possibilities 
was most likely. However, they suggest that they favor the idea that children with ASD 
exhibit increased intestinal permeability, which would lead to more SCFAs in the 
bloodstream. Their reason for favoring this hypothesis is based on findings by MacFabe 
et al. (2007), in which researchers found that propionic acid (an SCFA) can lead to ASD 
symptoms when injected into rats. Regardless of why SCFA levels were lower in children 
with ASD, all of the possibilities presented by Adams et al. (2011) imply that increased 
levels of SCFAs in the stool would be good. However, when comparing the ASD group 
taking probiotics to the ASD group not taking probiotics, the ASD probiotic group 
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actually had lower levels of SCFAs. This would indicate that probiotics are not 
beneficial, although the authors of this study do not make this connection. Overall, this 
study does not provide very strong support for the use of probiotics, especially since there 
was no mention of the specific probiotics being taken by the children.  
The third probiotic study was aimed at monitoring the changes in D-arabinitol 
(DA) in 22 children with ASD in Poland following probiotic treatment (Kałużna-
Czaplińska & Błaszczyk, 2012). They were interested in this metabolite because it comes 
from many pathogenic Candida species and other studies had shown it was elevated in 
children with ASD. While the focus of this thesis has been on bacteria of the gut 
microbiota, a review of this study is being included here because of the results they found 
regarding ASD symptoms following probiotic treatment with Lactobacillus acidophilus 
(strain Rosell-11) twice daily for 2 months. They found that children with ASD who 
received the probiotic showed significantly increased ability to concentrate and carry out 
orders. While these results are in favor of probiotic use for improving ASD symptoms, 
the sample size was very small and the authors did not mention what measurements they 
used to determine ASD symptoms. 
The fourth study examining the effects of probiotics in children with ASD studied 
10 children with ASD in Slovakia and compared them to 9 siblings and 10 healthy 
children (Tomova et al., 2015). The main measure these researchers were interested in 
was whether probiotic treatment could correct the dysbiosis seen in children with ASD. 
The probiotic used was one capsule three times per day for 4 months of “Children 
Dophilus,” which has Lactobacillus (three strains), Bifidumbacteria (two strains), and 
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Streptococcus (one strain). The researchers found that following this treatment, there was 
a significant decrease in Firmicutes levels such that the Bacteroidetes/Firmicutes level 
resembled that of the healthy children. They also found the Desulfovibrio levels 
decreased significantly after probiotic treatment. While children with ASD did not show 
significant differences in the levels of this species compared to controls, higher levels 
were found to be associated with increased autism severity, so this decrease seen with 
probiotics could be relevant.  
Santocchi et al. (2016) are currently in the process of completing a study to 
examine the effects of using a probiotic mixture called Vivomixx® in children with ASD. 
The authors believe a “well-controlled” clinical trial is needed and that other studies done 
to date have not adequately examined the relationship between probiotic use and ASD. 
Santocchi et al. are studying 100 preschoolers in Italy with ASD and either with GI 
symptoms or without and are placing them into four treatment arms, with an equal ratio 
of children in each group. The total length of treatment will be 6 months and the 
researchers conducting this study state they are interested in the effects on GI symptoms, 
core ASD symptoms, and brain function and connectivity. They will be assessing ASD 
symptoms via several methods including CARS, the Child Behavior Checklist for Ages 
1.5-5 (CBCL/1.5-5), the Repetitive Behavior Scale-Revised (RBS-R), and the Vineland 
Adaptive Behavior Sclaes II (VABS-II) (see Appendix I). Per clinicaltrials.gov, the 
estimated study completion date is November 2018, so the results will unfortunately not 
be available prior to the completion of this thesis. 
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One recent case study by Grossi et al. examined the effects that probiotic 
treatment had on a boy with ASD in Italy (Grossi, Melli, Dunca, & Terruzzi, 2016). The 
probiotic treatment for this child entailed VSL#3, which is a mixture of three 
Bifidobacteria species, five Lactobacilli species, and two Streptococci species and he 
received this treatment for 4 weeks. They found that this treatment not only alleviated his 
GI symptoms, but also led to an improvement in core ASD symptoms as measured by 
ADOS (see Appendix I). It is important to note that this boy had also been diagnosed 
with irritable bowel disease, so that could have played a role in the results they found. 
More recently, the results of a study examining the effects of a probiotic formula 
on children with ASD in Egypt were published (Shaaban et al., 2017). In this study, 30 
children with ASD were administered a probiotic formula containing Lactobacillus 
acidophilus, Lactobacillus rhamnosus, and Bifidobacteria longum for 3 months. Autism 
severity was assessed by ATEC (see Appendix I), and the researchers found that 
treatment with this probiotic formula led to a significant improvement in ATEC scores as 
well as an improvement in GI symptoms. The results of some of these aforementioned 
probiotic studies do provide support for the use of probiotics in children with ASD. 
However, studies with large sample sizes as well as extended follow up periods and a 
randomized placebo control group are needed before probiotic use can be validated as a 
treatment option.  
Antibiotics 
Upon review of the literature aimed at targeting the gut microbiota in children 
with ASD, the first study found using methods other than diet changes or 
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probiotics/prebiotics used vancomycin in 11 children with regressive-onset autism 
(Sandler et al., 2000). In this study, the authors hypothesized “that repeated antimicrobial 
use might [disrupt] a protective effect of indigenous intestinal organisms and [allow] 
colonization by one or more neurotoxin-producing species.” They developed this 
hypothesis after hearing reports from some parents that their children experienced an 
onset of autistic symptoms following chronic diarrhea after repeated broad-spectrum 
antimicrobial use (Sandler et al., 2000). They chose vancomycin because of its efficacy 
as well the fact that it is non-absorbable and stays in the GI tract. 
 Sandler et al. (2000) describe an “index case” of a 4.5 year old boy who 
developed autistic symptoms at around 19 months of age after having been treated three 
times over a period of 6 weeks with a 10-day course of broad-spectrum antibiotics for 
chronic otitis media. He then experienced chronic diarrhea, after which his ASD 
symptoms began. The authors note that he had normal motor, cognitive, and social 
development prior to this. They then treated him with oral vancomycin four times per day 
over the course of 12 weeks. After the sixth day, he started showing improvements 
including better behavior, ability to follow tasks, ability to achieve toilet training, 
increased vocabulary, and a decrease in repetitive behaviors. While the results were 
significant, his behavior quickly declined shortly after the vancomycin treatment was 
discontinued. These researchers then tried a similar treatment in 11 other children 
followed by 4 weeks of probiotic therapy (including Lactobacillus acidophilus, L 
bulgaricus, and Bifidobacterium bifidum). Improvements were seen in this group of 
children as well, but the results did not last, and most of them deteriorated once again 
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within 2 weeks after the vancomycin treatment was discontinued. Additionally, the 
authors note that many of the children did not take the probiotic because of unappealing 
taste, but this did not have any effect on the outcome of the treatment.  
One of the papers discovered in researching this topic was written by the father of 
a child with autism after he discovered that his son showed improvement in regard to his 
ASD symptoms following a 10 day course of amoxicillin for strep throat. According to 
his report, published in Microbial Ecology, his son began making eye contact, showed 
improved speech, became less insistent on following a specific routine, and had more 
energy, all things that had posed problems for him before (Rodakis, 2015). This father 
tracked his son’s behavior based on 20 parameters, and he notes that his son’s therapists 
made comments about his improvement not knowing that his son had taken antibiotics. 
He also makes a comment that he had seen some mild improvements in his son’s 
behavior previously when his son had a fever, although it is not clear if he is implying an 
infection related to the fever may have caused these changes or if it was medication given 
for the fever. Additionally, he states that other parents he talked to had seen 
improvements in their children’s ASD symptoms following antibiotic therapy, and some 
even said they gave their children antibiotics to help, however he does not provide any 
concrete examples. While he attributed positive benefits to antibiotic use in regards to his 
son’s ASD, he does also note that some parents said they believed their child’s ASD 
developed after antibiotic therapy, which is a theory that some have favored. In his 
report, this father provides results from some of the studies discussed here, and he argues 
that increased funding on this topic is needed. It is important to recognize that a sample 
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size of one child obviously has its limitiations. However, the fact that antibiotic therapy 
was able to seemingly improve a child’s ASD-related symptoms is interesting given that 
antibiotics are known to alter the gut microbiota. 
Microbiota Transfer Therapy 
 One recent study by Kang et al. (2017), which arguably shows some of the most 
promising results, treated 18 children aged 7-17 years old with ASD with what they 
termed Microbiota Transfer Therapy (MTT). This treatment included 2 weeks of oral 
antibiotic treatment with vancomycin followed by a bowel cleanse and then fecal 
microbiota transplant (FMT) with an initial high dose via either an oral or rectal route 
followed by a 7-8 week maintenance dose via the oral route as well as treatment with 
Prilosec (a proton pump inhibitor) to help the newly introduced bacteria survive. For the 
FMT part of the treatment, the researchers used standardized human gut microbiota 
(SHGM) in liquid form that is made from the stool of healthy individuals. It contains 
more than 99% bacteria and has been shown to be effective in the treatment of C. difficile 
infections, with 95% of individuals with recurrent C. difficile in one study of 43 
individuals being successfully treated after either one or two doses (Hamilton, 
Weingarden, Sadowsky, & Khoruts, 2012). 
Kang et al. (2017) monitored GI symptoms by having the parents of the children 
fill out the Gastrointestinal Symptom Rating Scale (GSRS) as well as a daily stool record 
(DSR). They used ADI-R to confirm a diagnosis of ASD and then used the Parent Global 
Impressions-III (PGI-III) to monitor changes in each child. To rate the severity of ASD 
and related symptoms, they used CARS, ABC, the Social Responsiveness Scale (SRS), 
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and VABS-II (see Appendix I). For analyzing the gut microbiota, they clustered 
sequences into operational taxonomic units (OTUs) (see Appendix II). The researchers of 
this study found that there was a significant decrease in the GSRS score for children in 
the ASD group, with the average drop in score compared to the baseline being 82%, and 
this improvement was seen even 8 weeks after MTT was discontinued. They also found 
that ASD-related behaviors significantly improved as rated by PGI-III, CARS, SRS, and 
ABC. Additionally, the average developmental age of the children with ASD increased 
by 1.4 years as measured by VABS-II. These improvements in GI symptoms and ASD-
related behaviors provide very promising results in support of the idea that targeting the 
gut microbiota can help with ASD symptoms, especially due to the numerous ASD 
assessments the researchers used to monitor changes.  
Kang et al. (2017) note that the treatment they employed led to temporary adverse 
effects such as tantrums, aggression, and hyperactivity, but this went away and was 
thought to be caused by vancomycin. This finding is contradictory to the beneficial 
effects of vancomycin reported by Sandler et al. (2000) and Rodakis (2015). Therefore, 
further research regarding the use of vancomycin in children with ASD is needed.  
 In regards to differences in the gut microbiota, Kang et al. (2017) found that 
samples from children with ASD + GI symptoms were significantly less diverse 
compared to those from neurotypical children without GI symptoms. After MTT, the 
diversity in children with ASD + GI symptoms increased significantly and this increase 
persisted 8 weeks after treatment ended, with diversity appearing similar to that seen in 
the neurotypical group. They also note that the bacterial diversity seen in the ASD + GI 
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symptoms group after treatment was similar to that of the donor bacterial community. 
Prior to treatment, children in the ASD group had significantly less Bifidobacterium 
compared to the neurotypical controls, but after treatment, its relative abundance 
increased. Additionally, the abundance of Prevotella and Desulfovibrio significantly 
increased after MTT. The authors note that the role of Desulfovibrio has been 
controversial, with some sources claiming its relationship to the human gut is commensal 
while others state it is detrimental (Kang et al., 2017). 
The children in this study were only followed for 8 weeks following the 
completion of MTT, so it possible that long-term effects could appear, but given the 
current information, MTT appears to be generally safe. Overall, Kang et al. (2017) make 
a compelling argument for the beneficial effects of MTT in treating children with ASD 
and GI symptoms, as it improved not only the GI symptoms of most of the children, but 
also some of their ASD-related behaviors. They also note that the fact that the gut 
microbiota of children with ASD following MTT became more like that of the 
neurotypical children is in line with the hypothesis that the gut microbiota may be “at 
least partially responsible for GI and ASD symptoms.” Despite the compelling evidence 
Kang et al. present, there are some downfalls to their research. One of these, which they 
acknowledge in their discussion, is that they did not include a control group, so the 
placebo effect may have been at play. They also note that having GI symptoms reported 
by the parents of the children instead of by a pediatric gastroenterologist could have led 
to unreliable results, since they claim it has been shown that parental reports and those by 
a specialist are sometimes in disagreement in regards to the specific GI 
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symptoms/diagnoses that a child is experiencing. Also, in terms of their study design, it 
would have been helpful if they had included a group of children with GI symptoms but 
without ASD and if they had treated those children with MTT in order to compare them 
to children with ASD. The children in the neurotypical group they studied did not suffer 
from any GI disorders, so it is not surprising that their gut microbiota would be different 
from that of children with GI symptoms who also have ASD. 
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DISCUSSION 
 
 While there seems to be a correlation between the gut microbiota and ASD, the 
results are not conclusive enough to say that an altered gut microbiota causes ASD. 
However, the studies discussed here do provide results that indicate further research into 
this field is warranted. One of the biggest issues found regarding this field is that there is 
tremendous variation in the methodology used, something that Rodakis (2015) noted in 
his report as well: there are wide variations in samples used (stool vs. biopsy), how they 
are collected, and how these samples are analyzed. Additionally, the fact that ASD is by 
definition a spectrum of disorders makes it probably unlikely that one single factor can be 
responsible for all cases. As some authors have hypothesized, it seems more likely that 
there is perhaps a subset of individuals with ASD who also experience GI symptoms, and 
that in this population, targeting the gut microbiota as a means of treatment could be 
beneficial. For example, Santocchi et al. (2016) believe it is possible that there could be a 
particular endophenotype of ASD, in which children with ASD suffer from GI symptoms. 
 Many of the studies looking at the role of the gut microbiota in ASD employ 
various methods for determining changes in GI symptoms. While having a pediatric 
gastroenterologist evaluate any child with GI symptoms in order to most accurately 
diagnose a child’s symptoms would be ideal, some of the studies presented here used 
parent questionnaires to evaluate GI symptoms. One study found that parents of children 
with ASD were able to identify that their child had some type of GI issue (92.1% 
correctly determined their child had a GI issue), but they were unable to accurately 
determine the specific type of GI issue. For example, 85% of children in the ASD+GI 
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symptom group were diagnosed as having functional constipation, but only 44.7% of 
parents in this group reported that their child suffered from constipation (Gorrindo et al., 
2012). While this can certainly affect the statistics that researchers present in terms of 
what GI issues are most common in children with ASD, it does not undermine the fact 
that children with ASD do in fact suffer from GI issues. 
In terms of methods used to study the relationship between the gut microbiota and 
ASD, using a mouse model can be very useful and cost effective, but results using mice 
are not directly translatable to humans. The gut microbiota of humans and that of the 
mouse are similar in that they both are dominated by Firmicutes and Bacteroidetes, but 
there are significant differences when looking at the genus level (Knight et al., 2017). 
Because of these underlying differences, Knight et al. point out that using a mouse model 
is suitable to study mechanisms but not for identifying specific species implicated in the 
biological processes that occur in humans. Therefore, those studies that monitor the 
effects of a particular treatment in a mouse model of ASD are not all that relevant to the 
study of ASD in humans. 
 Another issue with this field is that because ASD encompasses a spectrum of 
disorders and because the classification for ASD has changed over the years, it is 
impossible to directly compare results from time periods in which the classification for 
ASD was different. Also, due to advancements in the field of microbiology, there are 
many options available for identifying different bacterial species. In an ideal world, all 
researchers studying the role of the gut microbiota in ASD, or any disease, would use the 
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same methods for detecting different species. However, this is not the case, so it is 
important to note these differences when trying to draw broad conclusions. 
Another factor to consider with this field of research is that the gut microbiota is 
dependent on many factors, such that comparing results of studies from different regions 
and in different age groups is exceedingly difficult. For example, Tomova et al. (2015) 
point out that individuals in Europe tend to have a dominance of Firmicutes in their stool 
and that younger people tend to have less Bacteroidetes in their fecal samples. These 
differences make it difficult to draw broad conclusions from multiple studies. 
Additionally, because the gut microbiota is so complex, finding one treatment option for 
all children with ASD and GI symptoms would be nearly impossible. As Staley, Khoruts, 
and Sadowsky (2017) point out in a review article about the use of fecal microbiota 
transplantation in treating GI diseases, it is “unlikely that a single microbial species will 
serve as a sole therapeutic lynchpin.” Additionally, they also note that nobody has yet 
defined what makes up the “normal” microbiota of a healthy person. If we do not know 
what constitutes a healthy gut microbiota, it seems impossible to definitively say that a 
certain group of bacteria is to be blamed in ASD. 
Of all the studies discussed here, the MTT study by Kang et al. (2017) seems the 
most promising. That being said, proposing that fecal transplants be used widely would 
likely draw skepticism from many. However, it should be noted fecal microbiota 
transplantation is now considered “well established” as a treatment for recurrent C. 
difficile infections in the United States and Europe (Staley et al., 2017). Therefore, just 
because it is unusual, it should not be ruled out as a potential line of treatment for 
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children with ASD. More studies on this as a treatment option are needed and a placebo 
group should definitely be included in order to verify that the placebo effect is not taking 
place. 
There have been many developments over the years in terms of linking the gut 
microbiota to ASD. While many of these studies have their limitations, the research they 
have contributed is nonetheless important. Further research targeting the gut microbiota 
in children with ASD as well as examining the various ways in which these bacteria can 
interact with the brain of children will help further advance this field. If these studies 
continue to show that there is a relationship and if causation, rather than just correlation 
can be proven, advancements in this field may lead to treatment options for ASD. Given 
the prevalence of ASD and the burden that it places on families and caregivers of 
children with ASD, it is important that research into this field continue. 
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APPENDIX I: Tests Used to Diagnose and Assess ASD 
 
Aberrant Behavior Checklist (ABC): 
● The ABC “assesses problem behaviors in five areas common in children 
with ASD, including irritability, lethargy, stereotypy, hyperactivity, and 
inappropriate speech” (Kang et al., 2017). 
Autism Diagnostic Interview revised (ADI-R):  
● ADI-R is a structured interview which takes 2 hours. “It is one of the 
primary tools used for clinical diagnosis of autism and autism spectrum 
disorders. It is not designed to be a measure of autism severity but higher 
scores are generally consistent with more severe symptoms” (Kang et al., 
2017). 
Autism Diagnostic Observation Schedule (ADOS): 
● ADOS-CSS (calibrated severity score) was found to be the “best measure 
of ore features of ASD in pre-school children” (Wiggins et al., 2017). 
Wiggins et al. note the need for calibrated scores because the 
chronological age and language aptitude affects the total ADOS scores, 
which makes it an unreliable measure of ASD severity when looking at 
core symptoms. 
● Per a review article discussing assessment methods for ASD, ADOS is the 
“gold standard measure in clinics that evaluated children for autism” 
(Choueiri & Zimmerman, 2017). 
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● ADOS-2 is an updated version of ADOS. It “examines behaviors in two 
distinct domains. One takes into account the social affect (SA) and the 
other the restricted, repetitive behaviors (RRB). Both provide for the 
ADOS-2 comparison score, a metric for gauging overall autism severity” 
(Grossi et al., 2016). 
● Per Grossi et al. (2016), “it is well known tha ADOS score does not 
fluctuate spontaneously along time in ASD and is absolutely stable.”  
Autism Treatment Evaluation Checklist (ATEC): 
● This is “designed to provide a quantitative assessment of autism severity” 
and is made up of 4 subscales which are “1) 
speech/language/communication, 2) sociability, 3) sensory/cognitive 
awareness, and 4) health/physical behavior” (Adams et al., 2011). The 
scores are added up to provide an ATEC score. 
● Scores are provided by parents, but it has been shown that this score 
correlates well with those obtained using CARS (Geier, Kern, & Geier, 
2013). 
Child Behavior Checklist for Ages 1.5-5 (CBCL/1.5-5): 
● This tool is a “parent-completed measure of emotional, behavioral, and 
social problems in children aged 1.5-5 years. It was developed to assess a 
range or problem behaviors rather than ASD in particular” (Havdahl, von 
Tetzchner, Huerta, Lord, & Bishop, 2016). Per Havdahl et al., it is not 
adequate as a diagnostic tool due to the high number of false positives, 
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although it is useful for gathering information regarding behavioral 
problems.  
Childhood Autism Rating Scale (CARS): 
● This “can be used to both diagnose autism and ASD and asses the overall 
severity of the symptoms” (Kang et al., 2017). 
● This scale is a “well-established, professional-rated measure in that it is 
widely used and well validated” (Geier et al., 2013). 
Development Behavior Checklist Parent/Primary Caregiver Report (DBC-P): 
● This “is a ranking score test which consists of 96 items and can be scored 
using a three-point scale” (Parracho et al., 2010). 
Parent Global Impressions (PGI-III):  
● This tool is used to determine changes in 17 autism related symptoms. It is 
completed by parents and it was “found to be more reliable to ask parents 
directly about observed changes than to have them estimate symptoms 
severity at the beginning and end and then compute a difference” (Kang et 
al., 2017). 
Repetitive Behavior Scale-Revised (RBS-R): 
● This questionnaire is completed by parents and is used to assess repetitive 
and restrictive behaviors. It was found to be a “cost effective parent-report 
measure” that is reliable and a “viable means of assessing repetitive 
behavior in toddlers with autism” (Schertz, Odom, Baggett, & Sideris, 
2016). 
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Social Responsiveness Scale (SRS): 
● This “assesses social impairments, a core issue in autism, including social 
awareness, social information processing, capacity for reciprocal social 
communication, social anxiety/avoidance, and autistic preoccupations and 
traits” (Kang et al., 2017). 
Total Behaviour Problem Score (TBPS): 
● This score is “an overall indicator of behavioural/emotional disturbances 
and is calculated by summation of the scores for all 96 items [on the DBC-
P]. In addition, the individual items are categorized into five sub-scales 
that measure disturbance in five dimensions: disruptive/antisocial 
behavior, self-absorbed behaviour, communication, anxiety problems, and 
social-relating problems” (Parracho et al., 2010). 
Vineland Adaptive Behavior Scales II (VABS-II): 
● This test is neither diagnostic nor specific to a diagnosis of ASD because it 
also measures adaptive behavior (like living skills and motor skills), which 
makes it such that other co-occuring conditions that some children with 
ASD have could affect the scores (Wiggins et al., 2017). 
● It is a “measure of the functioning level in four different domains: 
communication, daily living skills, socialization, and motor skills” (Kang 
et al., 2017). 
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APPENDIX II: Methods Used to Classify Bacteria  
 
Below, a brief overview of advancements made in the field of classifying bacteria 
has been provided based on the summary given in a review article about the human 
microbiome (Knight et al., 2017). This is relevant seeing as the foundation of this field of 
study is based on classifying differences in the gut microbiota of children with ASD.  
Before the advent of genetic sequencing, researchers in the field of microbiology 
were limited in terms of the techniques available to them to classify bacteria. They had to 
rely on morphology-based methods as well as cell staining characteristics and the ability 
of a bacterial population to carry out biochemical reactions in order to group different 
bacteria. This of course did not allow scientists to classify organisms into phylogenetic 
groups accurately. Then, in the 1970s, Carl Woese revolutionized the way in which 
organisms were classified by discovering that ribosomal RNA (rRNA) evolved much 
more slowly which allowed researchers to group bacteria based on a phylogenetic 
framework in which 11 major microbial phyla were identified. Following this discovery, 
it was determined that there are certain regions of the 16S rRNA sequence in microbial 
organisms that are highly conserved in each phyla across even long evolutionary periods. 
Based on these conserved regions, primers were developed for reverse-transcriptase-
mediated direct sequencing which allowed researchers to sequence RNA genes and to 
group a particular bacteria into a phyla. 
 As more developments in the field of sequencing were made, including using 
PCR and automated DNA sequencing machines, it was determined that more than 1,000 
bacterial phyla exist. Now, there are next-generation sequencing techniques, which allow 
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scientists to obtain “millions of reads for less than once cent per read.” With so many 
sequences, researchers began grouping them into OTUs and defined sequences that were 
97% identical as being equivalent to belonging to the same species. Tools were then 
developed to more effectively analyze similarity between sequences such that now 
researchers can cluster sequences based on various parameters. In the mid 2000s, UniFrac 
was developed which takes phylogeny into account when comparing different microbial 
communities. As time goes on, it is likely that even faster and more specific methods of 
analyzing microbial groups will be developed, however, for now, the current techniques 
being used “have been very useful for functional investigations” (Knight et al., 2017). 
 Researchers employing a UniFrac analysis have two measures that they can use to 
determine the diversity of a bacterial community. One of these is unweighted UniFrac, 
which is a qualitative measure that uses the presence or absence of data for its analysis 
and ignores relative abundance. The other method, weighted UniFrac, is a quantitative 
measure which takes into account the relative abundance of each organism (Lozupone, 
Hamady, Kelley, & Knight, 2007). Per Lozupone et al., using a qualitative analysis is 
better at detecting the effects of different founding populations. As an example, they say 
it would be good at determining the source of bacteria that initially colonize the gut of 
newborn mice. In contrast, they say that a quantitative analysis is better at detecting the 
effects of factors like nutrient availability. 
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